Endoscopic treatment of primary grade V vesicoureteral reflux using hyaluronic acid copolymer (DX/HA)

被引:8
|
作者
Hunziker, Manuela [2 ]
Mohanan, Nochiparambil [1 ]
D'Asta, Federica [2 ]
Puri, Prem [1 ,2 ]
机构
[1] Our Ladys Hosp Sick Children, Childrens Res Ctr, Dublin 12, Ireland
[2] Natl Childrens Hosp, Dublin, Ireland
关键词
Vesicoureteral reflux; Endoscopic treatment; Renal scarring; MANAGEMENT;
D O I
10.1007/s00383-010-2650-1
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Since DX/HA was approved by the Food and Drug Administration in 2001 as an acceptable tissue-augmenting substance for subureteral injection, endoscopic treatment has become increasingly popular for treating vesicoureteral reflux (VUR). However, most paediatric urologists still continue to recommend ureteral reimplantation as the treatment of choice in the management of grade V VUR. The purpose of this study was to prospectively evaluate the effectiveness of endoscopic subureteral injection of DX/HA in the treatment of grade V reflux. During 2001-2009, 56 children (35 males, 21 females) with primary grade V VUR underwent endoscopic treatment using DX/HA. Their ages ranged from 4 months to 11 years. Forty-nine patients had unilateral grade V VUR, and seven had bilateral grade V (63 refluxing ureters including 17 duplex systems). Renal scarring on dimercaptosuccinic acid was observed in 39 kidneys (mild scarring 13, moderate scarring 14 and severe scarring 12). In all patients, endoscopic injection was made after inserting the needle within the wide ureteral orifice. Renal ultrasound and voiding cystourethrogram was performed 3 months after the endoscopic treatment. If VUR had not resolved, the patient was considered for further endoscopic treatment. After the VUR was resolved, children were followed with renal ultrasound at 1 year and every 2 years thereafter. The VUR completely resolved after first injection of DX/HA in 33 (52.4%) ureters and downgraded to grade I VUR in 7 (11.1%) ureters. 19 (30.2%) ureters required a second injection, and 4 (6.3%) ureters required a third injection to resolve VUR. No children in this series needed reimplantation of ureters or presented with ureteral obstruction during follow-up. Endoscopic treatment with DX/HA is effective in eradicating grade V primary reflux. This simple and minimally invasive treatment should be offered to all parents of children with grade V VUR as an alternative to ureteral reimplantation.
引用
收藏
页码:977 / 979
页数:3
相关论文
共 50 条
  • [1] Endoscopic treatment of primary grade V vesicoureteral reflux using hyaluronic acid copolymer (DX/HA)
    Manuela Hunziker
    Nochiparambil Mohanan
    Federica D’Asta
    Prem Puri
    Pediatric Surgery International, 2010, 26 : 977 - 979
  • [2] Randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR)
    Garcia-Aparicio, L.
    Blazquez-Gomez, E.
    Martin, O.
    Perez-Bertolez, S.
    Arboleda, J.
    Soria, A.
    Tarrado, X.
    WORLD JOURNAL OF UROLOGY, 2018, 36 (10) : 1651 - 1656
  • [3] Randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR)
    L. García-Aparicio
    E. Blázquez-Gómez
    O. Martin
    S. Pérez-Bertólez
    J. Arboleda
    A. Soria
    X. Tarrado
    World Journal of Urology, 2018, 36 : 1651 - 1656
  • [4] Incidence and risk factors for calcification after dextranomer/hyaluronic acid (Dx/HA) copolymer injection for vesicoureteral reflux
    Soria-Gondek, Andrea
    Martin-Sole, Oriol
    Perez-Bertolez, Sonia
    Martin-Lluis, Alba
    Tarrado-Castellarnau, Xavier
    Garcia-Aparicio, Luis
    JOURNAL OF PEDIATRIC UROLOGY, 2021, 17 (03) : 401.e1 - 401.e9
  • [5] Endoscopic treatment of vesicoureteral reflux with polyacrylate polyalcohol copolymer and dextranomer/hyaluronic acid in adults
    Turk, Akif
    Selimoglu, Ahmet
    Demir, Kadir
    Celik, Osman
    Saglam, Erkin
    Tarhan, Fatih
    INTERNATIONAL BRAZ J UROL, 2014, 40 (03): : 379 - 383
  • [6] The role of endoscopic treatment in the management of grade V primary vesicoureteral reflux
    Menezes, Maria N.
    Puri, Prem
    EUROPEAN UROLOGY, 2007, 52 (05) : 1505 - 1510
  • [7] Endoscopic treatment of moderate and high grade Vesicoureteral reflux in infants using dextranomer/hyaluronic acid
    Puri, Prem
    Mohanan, Nochiparambil
    Menezes, Maria
    Colhoun, Eric
    JOURNAL OF UROLOGY, 2007, 178 (04) : 1714 - 1716
  • [8] Long-term outcome of randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR)
    Garcia-Aparicio, Luis
    Martin-Sole, Oriol
    Capdevila-Vilaro, Blanca
    Perez-Bertolez, Sonia
    WORLD JOURNAL OF UROLOGY, 2023, 41 (10) : 2855 - 2859
  • [9] Long-term outcome of randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR)
    Luis Garcia-Aparicio
    Oriol Martin-Sole
    Blanca Capdevila-Vilaro
    Sonia Perez-Bertolez
    World Journal of Urology, 2023, 41 : 2855 - 2859
  • [10] Long-Term Clinical Outcomes and Parental Satisfaction After Dextranomer/Hyaluronic Acid (Dx/HA) Injection for Primary Vesicoureteral Reflux
    Lightfoot, Michelle
    Bilgutay, Aylin N.
    Tollin, Noah
    Eisenberg, Scott
    Weiser, Jake
    Bryan, Leah
    Smith, Edwin
    Elmore, James
    Scherz, Hal
    Kirsch, Andrew J.
    FRONTIERS IN PEDIATRICS, 2019, 7